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there is an active debate on the best approach to evaluate new cardiovascular risk factors. 
the divergent views have been most clearly laid 
out in the case of C-reactive protein (Crp) and its 
incremental value over conventional cardiovascular 
risk factors. advocates of Crp argue that its addi-
tion improves global measures of fit,1 while others 
point out that it does not improve measures of dis-
crimination.2,3 Discussions surrounding this debate 
have largely been technical, focusing on unique 
data sources and specific analytic approaches. 
the underlying principles, in contrast, have not 
been sufficiently highlighted. this paper presents a 
clinical perspective on the potential value of adding 
new cardiovascular risk factors to current methods 
for risk stratification. it proposes that novel risk 
factors should be evaluated by their effects on the 
population risk distribution curve, which presents 
the probability of occurrence of different levels of 
risk in a population as determined by a predic-
tive model. Broader population risk distribution 
curves represent superior risk stratification. Last, 
it should be recognized that there are many correct 
ways to risk-stratify a population and that the best 
approach ultimately depends on the clinical goals.
THE USE OF RISk MODELS IS TO STRATIFY RISk
the goal of risk stratification is to identify sub-
populations of differing cardiovascular risk within 
a larger general population to allow interventions 
to be employed selectively. Mathematic risk models 
must be applied to populations to determine their 
clinical utility. New cardiovascular risk factors 
that do not improve risk stratification within these 
models are not of clinical value, although they may 
increase scientific understanding or reveal new 
opportunities to develop preventive measures. 
applying a predictive model to an entire popula-
tion generates a population risk distribution curve. 
these are rarely presented in the cardiovascular lit-
erature but have important implications for assess-
ing the value of risk factors. We have been unable to 
locate a graph depicting the population distribution 
of cardiovascular risk determined by a framingham 
risk score, despite the widespread use of this risk 
score in the literature. an example of this is depicted 
in figure 1. this population risk distribution curve 
shows how frequently patients with different lev-
els of cardiovascular risk occur in the population. 
as expected, the higher their cardiovascular risk, 
the less often these patients are encountered. it is 
uncommon to find healthy patients with a 10-year 
risk >20%, the range expected for patients with cor-
onary artery disease. Graphs of this type represent 
a valuable way to evaluate the clinical importance 
of risk factors. Neither global measures of fit nor 
the receiver operating characteristic (rOC) curve so 
directly communicate the results of the risk stratifi-
cation process.
BROADER RISk DISTRIBUTION 
CURVES REPRESENT SUPERIOR RISk 
STRATIFICATION
absent any information about risk factors, all 
members of the population would be assigned the 
same risk. the risk distribution “curve” would be 
a spike at the mean population risk. as risk fac-
tors are added to a mathematic risk model, the 
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risk distribution curve should progressively widen, 
so long as the risk factors contribute additional 
information. figure 2 provides a hypothetical 
example of risk distribution curves of increasing 
width, demonstrating improved risk stratification. 
the increasing width shows an increasing ability to 
separate the population into subgroups of higher 
and lower risk.
if two mathematic risk models produce identical 
risk distribution curves when applied to the same 
population, then the risk stratification of the two 
models is equivalent. real-world data are unlikely 
to generate mathematically identical risk distri-
bution curves; however, similar risk distribution 
curves should be considered clinically equivalent, 
even if there are mathematic differences.
RISk DISTRIBUTION CURVES AND 
ROC CURVES CONTAIN IDENTICAL 
INFORMATION
the rOC curve, which depicts the relationship 
between sensitivity and specificity, has been an 
important tool for assessing diagnostic methods 
and predictive models.4 Diamond5 showed that 
the rOC curve for a risk model can be calculated 
from the population risk distribution. since the 
rOC curve can be derived from the risk distri-
bution curve (and vice versa), these curves con-
tain identical information. this means that the 
mathematic analyses of the rOC curve in the risk 
factor research literature can be better understood 
simply by evaluating the corresponding risk dis-
tribution curve.
Because the rOC curve and the risk distribution 
curve contain identical information, properties of 
one curve must correspond to properties of the 
other. the area under the rOC curve (the rOC 
curve aUC), used to compare both diagnostic 
methods and predictive models, is an example. 
although the rOC curve aUC is commonly under-
stood to measure the overlap of the risk distribu-
tion curves of patients with and without events, 
also known as discrimination, it is equally valid to 
consider the rOC curve aUC as a measure of the 
width of the population risk distribution curve. for 
example, the 3 population risk distribution curves 
with increasing width in figure 2 have rOC curve 
aUCs of 0.55, 0.65, and 0.75. Cook6 provides a 
similar example using the b distribution.
THERE ARE MANY “CORRECT” WAYS TO 
RISk-STRATIFY A POPULATION
for diagnostic methods, there is only one way to 
be correct: perfectly discriminate between patients 
with and without a disease. this is the definition 
of a gold standard or perfect test. for a predictive 
model to match this performance, it would need 
to identify patients who will or will not have an 
event in the future. Unfortunately, this is not pos-
sible because the occurrence of events is random 
or stochastic.
an alternative and more realistic criterion 
is that a predictive model is correct if it accu-
rately assigns risk to different subpopulations. 
this property is referred to as calibration. it is 
commonly evaluated by comparing the observed 
to predicted risk for each decile of risk.7 for a 
given population, there will be a multitude of 
risk stratification methods, all of which are cor-
rect or calibrated. however, because they utilize 
different risk factors, these methods will assign 
different risks to the same individual. Consider 
risk-stratifying the same population twice, once 
by systolic pressure and once by low-density 
lipoprotein cholesterol. assume the correspond-
ing cardiovascular risk for each decile was the 
same for the 2 risk factors. then the risk strati-
fication of the population by the 2 risk factors is 
identical. But patients with low blood pressure 
may have high low-density lipoprotein cholester-
ol, and vice versa, so individuals may be assigned 
very different risks depending on which risk fac-
tor is used to risk stratify the population.
Figure 1 . Approximation to the frequency distribution 
of 10-year cardiovascular risk in US adults without 
cardiovascular disease or cardiovascular disease risk 
equivalents . This distribution (an exponential distribu-
tion with a lambda of 17) assigns patients to low, inter-
mediate, and high risk in the same proportions reported 
in the literature .12
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DISCUSSION
Because the goal of risk stratification is to identify 
subpopulations of differing cardiovascular risk, the 
population risk distribution curve is the most useful 
way to assess a predictive method’s risk stratifica-
tion in a given population. Neither global measures 
of fit nor rOC curves show this directly.
framingham risk models are currently able 
to identify adult patients without cardiovascular 
disease with 10-year risks ranging from <1% to 
>30%. figure 1 (an approximation) illustrates the 
corresponding population risk distribution.
it is unknown whether this risk stratification 
can be improved. Newer risk factors8 or even 
measures of carotid atherosclerosis combined with 
Crp9 have not improved risk stratification using 
conventional risk factors. Diamond5 showed that 
risk models have limited discriminatory ability. 
as discussed above, perfect discrimination would 
mean that a predictive method could identify 
patients who will or will not have an event in the 
future. But making accurate predictions over a 
10-year period is only possible in deterministic sys-
tems (eg, prediction of eclipses in the solar system). 
the occurrence of clinical events in low-risk indi-
viduals is often thought to indicate that improved 
predictive methods are possible, but as long as the 
predicted number of events match the observed 
number of events in a low-risk subpopulation, this 
is not the case.
in comparing risk models, one should recognize 
that the predicted risk for individual patients can 
vary between calibrated models. an example of 
this for univariate risk models using systolic blood 
pressure and low-density lipoprotein cholesterol 
was given previously. if additional risk factors were 
added to such univariate models, patients with 
high levels of the additional risk factor would be 
assigned higher risks, while those with low levels of 
the additional risk factor would be assigned lower 
risks. this would occur throughout the risk dis-
tribution curve, ensuring extensive scrambling or 
reassortment of individual patients with the addi-
tion of each new risk factor. this would also occur 
even if the population risk distribution curve is not 
changed by the additional risk factors. ridker and 
colleagues10 described 2 calibrated multivariate 
models that differ in the number of risk factors. 
in spite of having the same discrimination, these 
models classified many patients into different risk 
strata. in this situation, the risk distribution curves 
should be the same, and thus the number of patients 
moved out of a risk stratum will be balanced by the 
number of patients moved into that risk stratum 
when additional risk factors are added.
reynolds and associates11 compared 3 cardio-
vascular risk models that predict similar numbers 
of patients above the same level of risk with a 
simulated population and showed limited concor-
dance in the individuals identified. Lack of concor-
dance when multiple cardiovascular risk models 
are used to risk stratify the same population has 
not been extensively studied. however, it should 
be expected that there will be a large number of 
cardiovascular risk models based on different risk 
factors that are calibrated and produce similar 
population risk distribution curves, but these mod-
els may classify individuals differently.
this should be contrasted with the situation 
with diagnostic testing. in that case, there is only 
one correct answer for an individual, “intermedi-
ate” probability indicates a poor assessment, and 
further testing is indicated. But once a population 
has been risk-stratified by a calibrated model, 
further testing may be counterproductive, even 
for “intermediate-risk” patients. further testing 
may simply replace one reasonable population risk 
stratification with another equivalent one, while 
the reassignment of individuals leads to confusion 
and wasted effort. it is tempting to use multiple 
risk estimation methods in the same patient to 
avoid missing something. this will lead to errone-
ous risk stratification of the population and over-
treatment, as the number of individuals identified 
as high-risk by any one of a number of risk models 
Figure 2 . Sinusoidal population risk distribution curves 
with the same mean risk but increasing width, indicat-
ing improved risk stratification . The broader the risk 
distribution curve, the better the separation of patients 
of differing risks .
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will exceed the number of high-risk individuals in 
the population.
Whether a risk factor contributes to risk strati-
fication is a separate issue from whether it is 
causative or should be treated even if a therapy 
is available. Cook6 has shown that systolic blood 
pressure, total cholesterol, high-density lipoprotein 
cholesterol, or smoking status can be removed 
from models including all the framingham risk 
factors with minimal change in discrimination. it 
appears that only a few cardiovascular risk factors 
are required to adequately risk-stratify the popula-
tion. treatment decisions need to be based on clini-
cal trials, not on whether addition of a risk factor 
improves risk stratification.
how well a model risk-stratifies a population 
should be the primary criterion for choosing a 
method for clinical use, but there are additional 
criteria that could be considered. these would 
include cost, precision, reproducibility, availability, 
safety of the test, and whether modification of the 
risk factor reduced risk.
there is a bewildering array of new risk factors 
under investigation. Examples include Crp, coro-
nary artery calcium score, and measures of arterial 
stiffness. from a clinical perspective, if risk factors 
do not improve risk stratification as assessed by 
the population risk distribution curve, they are 
not improving patient care. risk factor evaluation 
by regression methods only measures association 
and provides no information on the population 
risk distribution curve. in contrast, the standard 
measure of discrimination, the rOC curve aUC, 
does. few cardiovascular risk factors have been 
appropriately evaluated for clinical utility. Crp 
has been appropriately evaluated and has failed to 
demonstrate clinical utility.1–3 therefore, at pres-
ent it does not appear that Crp needs to be added 
to the framingham risk factors for cardiovascular 
risk calculation. although diagnostic methods 
arrive at unique assessments for an individual 
patient, predictive methods do not, even if they 
are calibrated and have similar population risk 
distribution curves. in this case, restratification of 
a population may be unhelpful.
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